T1	HMM 452 460	efficacy
T2	HMM 465 471	safety
T3	HMM 1666 1695	were HIV-free infant survival
T4	HMM 1714 1739	months; HIV-free survival
T5	HMM 1778 1807	breastfed; AIDS-free survival
T6	HMM 1833 1859	and serious adverse events
T7	HMM 1875 1881	babies
T8	HMM 2148 2187	The cumulative rate of HIV transmission
T9	HMM 2509 2520	(p=0Â·029).
T10	HMM 2521 2560	The cumulative rate of HIV transmission
T11	HMM 2788 2831	intended to breastfeed, the cumulative rate
T12	HMM 2987 3015	single-dose nevirapine group
T13	HMM 3087 3114	in a different publication.
T14	HMM 3115 3155	The incidence of laboratory and clinical
T15	HMM 3296 3305	pregnancy
T16	HMM 3310 3355	breastfeeding is safe and reduces the risk of
